News & Updates

Treatment with semaglutide 2.4 mg results in clinically meaningful weight loss, irrespective of baseline antidepressant (AD) use, among adults with overweight/obesity, reports a post hoc study of the Semaglutide Treatment Effect for People with obesity (STEP).

Treatment with trastuzumab deruxtecan (T-DXd) provides sustained antitumour activity and shows a consistent safety profile in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (mBC) previously treated with trastuzumab emtansine (T-DM1), as shown by the updated survival results from the phase II DESTINY-Breast01 trial.

Metastasis-free survival (MFS) is still a good proxy for overall survival (OS) as endpoint in the current era, wherein patients have more access to docetaxel and other treatments for metastatic castrate-resistant prostate cancer (mCRPC), according to a study.